Pfizer Launches Macugen In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer launched Macugen (pegaptanib sodium injection) in Japan Oct. 14. The first aptamer drug in Japan, Macugen is an anti-vascular endothelial growth factor therapy to help reduce the risk of vision loss in neovascular age-related macular degeneration. Priced at ¥123,457 per set, the 0.3 milligram injection kit will be marketed by medical representatives who are specialized in ophthalmologic drugs. (Click here for more - Japanese language
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.